Cite
Otsuka T, Shirakawa T, Shimokawa M, et al. Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. Int J Clin Oncol. 2021;26(5):951-953doi: 10.1007/s10147-021-01880-5.
Otsuka, T., Shirakawa, T., Shimokawa, M., Koga, F., Kawaguchi, Y., Ueda, Y., Nakazawa, J., Komori, A., Otsu, S., Arima, S., Fukahori, M., Okabe, Y., Makiyama, A., Taguchi, H., Honda, T., Shibuki, T., Nio, K., Ide, Y., Mizuta, T., Mitsugi, K., & Ureshino, N. (2021). Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. International journal of clinical oncology, 26(5), 951-953. https://doi.org/10.1007/s10147-021-01880-5
Otsuka, Taiga, et al. "Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study." International journal of clinical oncology vol. 26,5 (2021): 951-953. doi: https://doi.org/10.1007/s10147-021-01880-5
Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Mizuta T, Mitsugi K, Ureshino N. Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. Int J Clin Oncol. 2021 May;26(5):951-953. doi: 10.1007/s10147-021-01880-5. PMID: 33656656.
Copy
Download .nbib